2015 China cancer report challenges China's pharmaceutical industry

Source: U.S and Chinese medicine sources On February 1, 2016, Professor He Jie and his colleagues from the Cancer Institute of the medical college published the 2015 China cancer epidemic statistical report on Ca cancer jclin The research shows that the distribution of cancer in China is significantly different from that in the West The cancer of liver, lung, stomach and esophagus accounts for 60% of cancer patients in China, only 18% of cancer patients in the United States, which fully challenges the pharmaceutical industry in China According to the industry, all pharmaceutical companies should pursue the most profitable market, so multinational enterprises cannot be expected to solve China's multiple tumors first News event: Recently, Professor He Jie and his colleagues from Cancer Institute of Medical College published the 2015 China cancer epidemic statistical report on Ca cancer jclin This is a trend report based on a survey of 85 million people in 2000-2011 According to this study, 4.29 million new cancer patients and 2.81 million people died of cancer in China in 2015 The most common five tumors in men were lung cancer, gastric cancer, esophageal cancer, liver cancer, and colorectal cancer, while the most common five tumors in women were breast cancer, lung cancer, gastric cancer, colorectal cancer, and esophageal cancer These multiple cancers account for more than 60% of all cancers The main controllable carcinogenic factors are chronic infection (hepatitis, HPV, etc.), smoking, and environmental pollution The same issue also published cancer epidemic data in the United States The top four tumors in the United States are lung cancer, breast cancer, prostate cancer, and colorectal cancer Source analysis: This study shows that the distribution of cancer in China is significantly different from that in the west, accounting for 60% of cancer patients in China, only 18% of cancer patients in the United States are liver, lung, stomach and esophagus The discussion part of the article points out that the main cancers in China are more deadly than those in the United States On the one hand, it may be related to the tumor itself, on the other hand, it may also be related to the western pharmaceutical companies paying more attention to the research and development of new drugs for their own multiple tumors, so there are more drugs to control these cancers In the past 20-25 years, the mortality of multiple tumors such as lung cancer, breast cancer, prostate cancer, and colorectal cancer in the United States has decreased significantly, while the mortality of multiple tumors such as liver, stomach, and esophageal cancer in China has hardly changed It shows that the progress of drugs and detection technology in the world does not benefit many cancer patients in China All pharmaceutical companies must pursue the most profitable market, so multinational enterprises cannot be expected to solve China's multiple tumors first Although George Merck said that drugs are for patients, the drugs here are not all drugs and patients are not all patients China's unique diseases still rely more on China's capital and national pharmaceutical industry However, in the period when Chinese enterprises are unable to compete with multinational enterprises in an all-round way, developing China's unique market also provides a relatively moderate living space for Chinese pharmaceutical enterprises Of course, this is obvious, but there are not many enterprises engaged in this business Today's talent, technology and capital are not problems, mainly the need for changes in ideas What Chinese enterprises need is to reduce the practice of blindly tracking foreign hot targets, but to follow the international advanced R & D mode to develop new drugs needed by their own market Imitation should be like gods, not just shapes Now, PD-1 antibody has shown considerable efficacy in most of the solid tumors mentioned above, which can be used as a main treatment Other therapies may not be available in the western market, but in fact, relevant technologies may be quite mature For example, targeting therapy for protein kinase, angiogenesis inhibitors, epigenetic drugs and so on are mainly targeted at variant genes of Western multiple tumors, but the whole technical framework including compound types, screening optimization procedures, and patient selection rules are applicable to drug development for key targets of multiple tumors in China The basic research on these targets should be relatively mature The key is that Chinese investors are willing to take the risk of new drug development More than 100 years ago, Mr Liang Qichao said that "if you don't let it go, you can destroy the world; if you take risks, you can create the world." Don't we all talk about feelings now? It is hoped that Chinese capital can shoulder the responsibility of solving China's endemic diseases.